UY26832A1 - Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer - Google Patents

Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer

Info

Publication number
UY26832A1
UY26832A1 UY26832A UY26832A UY26832A1 UY 26832 A1 UY26832 A1 UY 26832A1 UY 26832 A UY26832 A UY 26832A UY 26832 A UY26832 A UY 26832A UY 26832 A1 UY26832 A1 UY 26832A1
Authority
UY
Uruguay
Prior art keywords
drugs
manufacture
parapoxvirus ovis
straps
against cancer
Prior art date
Application number
UY26832A
Other languages
English (en)
Inventor
Gudrun Theiss
Tobias Schlapp
Angela Siegling
Andreas Knorr
Claudia Hirth-Dietrich
Olaf Weber
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122451A external-priority patent/DE10122451A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of UY26832A1 publication Critical patent/UY26832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Abstract

La presente invención se refiere al uso de cepas de Parapoxvirus ovis como agente inmonuterapéutico en debilitamientos inmunológicos de naturaleza infecciosa o no infecciosa, así como al uso de cepas de Parapoxvirus ovis para el tratamiento de enfermedades tumorales, infecciones virales y las enfermedades que acompanan a éstas, así como al uso de cepas de Parapoxvirus ovis para la fabricación de medicamentos para el uso en hombres y animales.
UY26832A 2000-07-11 2001-07-11 Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer UY26832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10033582 2000-07-11
DE10122451A DE10122451A1 (de) 2000-07-11 2001-05-09 Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs

Publications (1)

Publication Number Publication Date
UY26832A1 true UY26832A1 (es) 2002-01-31

Family

ID=26006335

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26832A UY26832A1 (es) 2000-07-11 2001-07-11 Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer

Country Status (36)

Country Link
US (1) US6685950B2 (es)
EP (1) EP1303286B1 (es)
JP (1) JP5037775B2 (es)
CN (1) CN1455674B (es)
AR (1) AR029954A1 (es)
AT (1) ATE324115T1 (es)
AU (2) AU7063101A (es)
BG (1) BG107448A (es)
CA (1) CA2415397C (es)
CY (1) CY1105408T1 (es)
CZ (1) CZ200371A3 (es)
DE (1) DE50109630D1 (es)
DK (2) DK1303286T3 (es)
EE (1) EE200300018A (es)
ES (1) ES2262663T3 (es)
FI (1) FI20030037A (es)
GB (1) GB2381454B8 (es)
HK (1) HK1054329B (es)
HR (1) HRP20030096A2 (es)
HU (1) HUP0400479A3 (es)
IL (1) IL153643A0 (es)
LT (1) LT5079B (es)
LU (1) LU90997B1 (es)
LV (1) LV12990B (es)
MA (1) MA26927A1 (es)
MX (1) MXPA03000279A (es)
NO (1) NO20030082L (es)
NZ (1) NZ523534A (es)
PL (1) PL366397A1 (es)
PT (1) PT1303286E (es)
RU (1) RU2003104525A (es)
SE (1) SE0300034L (es)
SI (1) SI21122A (es)
SK (1) SK362003A3 (es)
UY (1) UY26832A1 (es)
WO (1) WO2002004002A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
HU230198B1 (hu) * 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
NZ512341A (en) 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
WO2003050135A2 (en) 2001-12-07 2003-06-19 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
PL220781B1 (pl) * 2002-04-19 2016-01-29 Bavarian Nordic As Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN
BRPI0313559B8 (pt) * 2002-09-05 2021-05-25 Bavarian Nordic As método para o cultivo de células primárias e para a amplificação de vírus sob condições isentas de soro
BRPI0513321B1 (pt) * 2004-07-13 2022-03-08 Aicuris Gmbh & Co. Kg Vírus parapox em combinação com outros agentes antivirais para o tratamento de doenças virais
PL1951274T3 (pl) * 2005-11-24 2010-05-31 Aicuris Gmbh & Co Kg Parapoksywirusy w kombinacji z klasycznymi cytotoksycznymi środkami chemioterapeutycznymi jako biochemioterapia do leczenia raka
JP5004990B2 (ja) * 2009-03-31 2012-08-22 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
ES2626595T5 (es) * 2009-12-18 2021-11-24 Bavarian Nordic As Producción de IFN-lambda por células dendríticas convencionales y usos de las mismas
JP5699093B2 (ja) * 2012-01-05 2015-04-08 アイキュリス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフトＡｉＣｕｒｉｓ ＧｍｂＨ ＆ Ｃｏ． ＫＧ パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法
WO2023083943A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with antivirals
WO2023083950A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory virus infections in combination with immunomodulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3504940C2 (de) * 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
PL190401B1 (pl) * 1996-02-28 2005-12-30 Bayer Healthcare Ag Wytworzony rekombinacyjnie parapoxwirus pochodzący ze szczepu parapoxwirusa D 1701, sposób wytwarzania szczepionki, oraz rekombinacyjnie wytworzone PPV
WO1997037031A1 (en) * 1996-03-29 1997-10-09 University Of Otago Parapoxvirus vectors
JP3568208B2 (ja) * 1996-04-15 2004-09-22 マイヤー，アントン 弱毒化された非免疫原性ポックスウイルスまたはパラポックスウイルスからの多種有効性パラポックス免疫誘導剤の薬剤としての使用のための新規薬効
SE9700617D0 (sv) * 1997-02-21 1997-02-21 Kjell Alving New composition
DE19843222A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Verwendung von phosphororganischen Verbindungen zur therapeutischen und prophylaktischen Behandlung von Infektionen
JP2003517275A (ja) * 1998-11-02 2003-05-27 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 哺乳動物ｖｅｇｆレセプター−２に結合し、これを活性化するオルフウイルスｎｚ２由来の血管内皮細胞増殖因子様タンパク質

Also Published As

Publication number Publication date
WO2002004002A2 (de) 2002-01-17
CN1455674A (zh) 2003-11-12
GB2381454B (en) 2004-11-24
DK1303286T3 (da) 2006-08-28
GB2381454A (en) 2003-05-07
MA26927A1 (fr) 2004-12-20
MXPA03000279A (es) 2004-04-05
LV12990B (en) 2003-08-20
RU2003104525A (ru) 2004-06-27
LU90997B1 (en) 2003-01-08
HUP0400479A2 (hu) 2004-06-28
HRP20030096A2 (en) 2005-02-28
GB0302630D0 (en) 2003-03-12
CA2415397C (en) 2011-04-26
FI20030037A (fi) 2003-03-10
HK1054329A1 (en) 2003-11-28
IL153643A0 (en) 2003-07-06
SI21122A (sl) 2003-08-31
US6685950B2 (en) 2004-02-03
LT2003009A (en) 2003-08-25
HUP0400479A3 (en) 2006-02-28
JP5037775B2 (ja) 2012-10-03
SK362003A3 (en) 2003-07-01
CZ200371A3 (cs) 2003-04-16
ES2262663T3 (es) 2006-12-01
NO20030082D0 (no) 2003-01-08
NZ523534A (en) 2005-02-25
AR029954A1 (es) 2003-07-23
PT1303286E (pt) 2006-08-31
SE0300034D0 (sv) 2003-01-10
CN1455674B (zh) 2019-03-29
WO2002004002A3 (de) 2002-10-31
ATE324115T1 (de) 2006-05-15
EP1303286A2 (de) 2003-04-23
GB2381454A8 (en) 2007-10-23
DK200300015A (da) 2003-03-07
US20030021769A1 (en) 2003-01-30
LT5079B (lt) 2003-12-29
CA2415397A1 (en) 2002-01-17
BG107448A (bg) 2003-11-28
JP2004517807A (ja) 2004-06-17
HK1054329B (zh) 2005-10-07
SE0300034L (sv) 2003-03-03
DE50109630D1 (de) 2006-06-01
AU7063101A (en) 2002-01-21
EE200300018A (et) 2004-10-15
GB2381454B8 (en) 2007-10-23
PL366397A1 (en) 2005-01-24
NO20030082L (no) 2003-01-08
AU2001270631B2 (en) 2005-07-07
EP1303286B1 (de) 2006-04-26
CY1105408T1 (el) 2010-04-28

Similar Documents

Publication Publication Date Title
UY26832A1 (es) Uso de cepas de parapoxvirus ovis para la fabricacion de medicamentos antivirales y medicamentos contra el cancer
ECSP056138A (es) Dihidroquinazolinas sustituidas
UY27186A1 (es) Formulación farmacéutica
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
BRPI0416205A (pt) uso de antibióticos como adjuvantes de vacina
UY31106A1 (es) Formulaciones que contienen triazinonas y hierro
AR053775A1 (es) Nonadepsipeptidos acilados ii
WO2015058772A3 (en) Novel hcv culture systems and direct-acting antiviral sensitivity
CL2017002846A1 (es) Métodos de tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t.
UY28313A1 (es) Nonadepsipeptidos acilados
HK1097467A1 (en) Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
DOP2001000211A (es) Uso de cepas de parapoxvirus ovis para la fabricación de medicamentos antivirales y medicamentos contra el cancer
MX2017010806A (es) Formulacion de acido 18-beta-glicirretinico en combinacion con revesterol y metformina, usos y metodo de fabricacion.
PA8590801A1 (es) Derivados de nucleosido antivirales
PT1220676E (pt) Prevencao do cancro colorrectal
WO2019068905A3 (en) Feline vaccines conferring early protection
EP1868639A4 (en) METHODS OF APPLICATION OF IONIZATION RAYS FOR THE THERAPY OF HIV INFECTION
Mallet et al. Chronic hepatitis E infection cured by pregnancy
BR112021006388A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero
WO2003000274A3 (en) Bacteriophage preparation for the treatment of intracellular bacterial infection
ATE406888T1 (de) Cyanoacrylat-zusammensetzungen für die therapeutische behandlungvon wunden, die eine revision erfordern
UY26945A1 (es) Alcanosulfonatos de fenoxifenilo
CO2023005389A2 (es) Vacuna terapéutica que comprende un antígeno específico de una enfermedad que no afecta al sistema nervioso central y nanopartículas y su uso
BR0008269A (pt) Uso de uma preparação de m. vaccae, e, método para tratamento de infecção viral crÈnica, excluindo infecção por hiv
MX2020011523A (es) Composicion farmaceutica adecuada para administracion vaginal en forma de ovulos y uso de la misma.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140905